REFERENCES
1. Carlisle E, Fischgrund JS. Bone morphogenetic proteins for spinal fusion. Spine J.
2005;5(suppl 5):240S-249S.
2. Ludwig SC, Kowalski JM, Boden SD. Osteoinductive bone graft substitutes. Eur Spine J.
2000;9(suppl 1):S119-S125.
3. Fischgrund JS, Mackay M, Herkowitz HN, et al. 1997 Volvo Award winner in clinical studies.
Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized
study comparing decompressive laminectomy and arthrodesis with and without spinal
instrumentation. Spine (Phila Pa 1976). 1997;22(24):2807-2812.
4. Bridwell KH, Sedgewick TA, O’Brien MF, et al. The role of fusion and instrumentation in the
treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord.
1993;6(6):461-472.
5. Dimar JR, 2nd, Glassman SD, Burkus JK, et al. Two-year fusion and clinical outcomes in 224
patients treated with a single-level instrumented posterolateral fusion with iliac crest
bone graft. Spine J. 2009;9(11):880-885.
6. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone
graft substitute. Spine (Phila Pa 1976). 2002;27(16 suppl 1):S26-S31.
7. Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in
women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976).
2012;37(23):E1464-E1468.
8. Bouchard JA, Koka A, Bensusan JS, et al. Effects of irradiation on posterior spinal fusions. A
rabbit model. Spine (Phila Pa 1976). 1994;19(16):1836-1841.
9. Hogevold HE, Grogaard B, Reikeras O. Effects of short-term treatment with corticosteroids
and indomethacin on bone healing. A mechanical study of osteotomies in rats. Acta
Orthop Scand. 1992;63(6):607-611.
10. Burchardt H, Glowczewskie FP, Jr, Enneking WF. The effect of Adriamycin and
methotrexate on the repair of segmental cortical autografts in dogs. J Bone Joint Surg
Am. 1983;65(1):103-108.
11. Nilsson OS, Bauer HC, Brostrom LA. Methotrexate effects on heterotopic bone in rats. Acta
Orthop Scand. 1987;58(1):47-53.
12. Lee TC, Ueng SW, Chen HH, et al. The effect of acute smoking on spinal fusion: an
experimental study among rabbits. J Trauma. 2005;59(2):402-408.
13. Brown CW, Orme TJ, Richardson HD. The rate of pseudarthrosis (surgical nonunion) in
patients who are smokers and patients who are nonsmokers: a comparison study. Spine
(Phila Pa 1976). 1986;11(9):942-943.
14. Zdeblick TA. A prospective, randomized study of lumbar fusion. Preliminary results. Spine
(Phila Pa 1976). 1993;18(8):983-991.
15. Boden SD, Sumner DR. Biologic factors affecting spinal fusion and bone regeneration. Spine
(Phila Pa 1976). 1995;20(suppl 24):102S-112S.
16. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of
single-level instrumented posterolateral fusions with recombinant human bone
morphogenetic protein-2compression resistant matrix versus iliac crest bone graft.
Spine (Phila Pa 1976). 2006;31(22):2534-2539; discussion 2540.
17. Kerr EJ, 3rd, Jawahar A, Wooten T, et al. The use of osteo-conductive stem-cells allograft in
lumbar interbody fusion procedures: an alternative to recombinant human bone
morphogenetic protein. J Surg Orthop Adv. 2011;20(3):193-197.
18. Gurr KR, McAfee PC, Warden KE, et al. Roentgenographic and biomechanical analysis of
lumbar fusions: a canine model. J Orthop Res. 1989;7(6):838-848.
19. Samartzis D, Shen FH, Matthews DK, et al. Comparison of allograft to autograft in
multilevel anterior cervical discectomy and fusion with rigid plate fixation. Spine J.
2003;3(6):451-459.
20. Ohtori S, Suzuki M, Koshi T, et al. Single-level instrumented posterolateral fusion of the
lumbar spine with a local bone graft versus an iliac crest bone graft: a prospective,
randomized study with a 2-year follow-up. Eur Spine J. 2011;20(4):635-639.
21. Sengupta DK, Truumees E, Patel CK, et al. Outcome of local bone versus autogenous iliac
crest bone graft in the instrumented posterolateral fusion of the lumbar spine. Spine
(Phila Pa 1976). 2006;31(9):985-991.
22. Kang J, An H, Hilibrand A, et al. Grafton and local bone have comparable outcomes to iliac
crest bone in instrumented single-level lumbar fusions. Spine (Phila Pa 1976).
2012;37(12):1083-1091.
23. Grabowski G, Cornett CA. Bone graft and bone graft substitutes in spine surgery: current
concepts and controversies. J Am Acad Orthop Surg. 2013;21(1):51-60.
24. Herkowitz HN, Kurz LT. Degenerative lumbar spondylolisthesis with spinal stenosis. A
prospective study comparing decompression with decompression and intertransverse
process arthrodesis. J Bone Joint Surg Am. 1991;73(6):802-808.
25. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a
replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term
(4 years) pivotal study. Spine (Phila Pa 1976). 2008;33(26):2850-2862.
26. Rihn JA, Kirkpatrick K, Albert TJ. Graft options in posterolateral and posterior interbody
lumbar fusion. Spine (Phila Pa 1976). 2010;35(17):1629-1639.
27. Summers BN, Eisenstein SM. Donor site pain from the ilium. A complication of lumbar
spine fusion. J Bone Joint Surg Br. 1989;71(4):677-680.
28. Banwart JC, Asher MA, Hassanein RS. Iliac crest bone graft harvest donor site morbidity. A
statistical evaluation. Spine (Phila Pa 1976). 1995;20(9):1055-1060.
29. Silber JS, Anderson DG, Daffner SD, et al. Donor site morbidity after anterior iliac crest
bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa
1976). 2003;28(2):134-139.
30. Delawi D, Dhert WJ, Castelein RM, et al. The incidence of donor site pain after bone graft
harvesting from the posterior iliac crest may be overestimated: a study on spine fracture
patients. Spine (Phila Pa 1976). 2007;32(17):1865-1868.
31. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma.
1989;3(3):192-195.
32. Arrington ED, Smith WJ, Chambers HG, et al. Complications of iliac crest bone graft
harvesting. Clin Orthop Relat Res. 1996(329):300-309.
33. Bae HW, Zhao L, Kanim LE, et al. Intervariability and intravariability of bone
morphogenetic proteins in commercially available demineralized bone matrix products.
Spine (Phila Pa 1976). 2006;31(12):1299-1306; discussion 1307-1298.
34. Mroz TE, Joyce MJ, Lieberman IH, et al. The use of allograft bone in spine surgery: is it
safe? Spine J. 2009;9(4):303-308.
35. Jamali A, Hilpert A, Debes J, et al. Hydroxyapatitecalcium carbonate (HACC) vs. plaster of
Paris: a histomorphometric and radiographic study in a rabbit tibial defect model. Calcif
Tissue Int. 2002;71(2):172-178.
36. Carter JD, Swearingen AB, Chaput CD, et al. Clinical and radiographic assessment of
transforaminal lumbar interbody fusion using HEALOS collagen-hydroxyapatite
sponge with autologous bone marrow aspirate. Spine J. 2009;9(6):434-438.
37. Neen D, Noyes D, Shaw M, et al. Healos and bone marrow aspirate used for lumbar spine
fusion: a case controlled study comparing healos with autograft. Spine (Phila Pa 1976).
2006;31(18):E636-E640.
38. Kitchel SH. A preliminary comparative study of radiographic results using mineralized
collagen and bone marrow aspirate versus autologous bone in the same patients
undergoing posterior lumbar interbody fusion with instrumented posterolateral lumbar
fusion. Spine J. 2006;6(4):405-411; discussion 411-402.
39. Vanek P, Bradac O, DeLacy P, et al. Comparison of 3 fusion techniques in the treatment of
the degenerative cervical spine disease. Is stand-alone autograft really the “gold
standard?”: prospective study with 2-year follow-up. Spine (Phila Pa 1976).
2012;37(19):1645-1651.
40. Walsh WR, Loefler A, Nicklin S, et al. Spinal fusion using an autologous growth factor gel
and a porous resorbable ceramic. Eur Spine J. 2004;13(4):359-366.
41. Siebrecht MA, De Rooij PP, Arm DM, et al. Platelet concentrate increases bone ingrowth
into porous hydroxyapatite. Orthopedics. 2002;25(2):169-172.
42. Cinotti G, Corsi A, Sacchetti B, et al. Bone ingrowth and vascular supply in experimental
spinal fusion with platelet-rich plasma. Spine (Phila Pa 1976). 2012;38(5):385-391.
43. Tsai CH, Hsu HC, Chen YJ, et al. Using the growth factors-enriched platelet glue in spinal
fusion and its efficiency. J Spinal Disord Tech. 2009;22(4):246-250.
44. Castro FP, Jr. Role of activated growth factors in lumbar spinal fusions. J Spinal Disord
Tech. 2004;17(5):380-384.
45. Acebal-Cortina G, Suarez-Suarez MA, Garcia-Menendez C, et al. Evaluation of autologous
platelet concentrate for intertransverse lumbar fusion. Eur Spine J. 2011;20(suppl
3):361-366.
46. Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a
substitute to autologous iliac crest bone grafting for spinal fusion procedures in the
United States. Spine (Phila Pa 1976). 2011;36(4):E274-E281.
47. Urist MR. Bone: formation by autoinduction. Science. 1965;150(3698):893-899.
48. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2
with tapered interbody cages. J Spinal Disord Tech. 2002;15(5):337-349.
49. Burkus JK, Sandhu HS, Gornet MF. Influence of rhBMP-2 on the healing patterns associated
with allograft interbody constructs in comparison with autograft. Spine (Phila Pa 1976).
2006;31(7):775-781.
50. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior
lumbar interbody fusion using recombinant human bone morphogenetic protein-2.
Spine (Phila Pa 1976). 2002;27(21):2396-2408.
51. Glassman SD, Carreon L, Djurasovic M, et al. Posterolateral lumbar spine fusion with
INFUSE bone graft. Spine J. 2007;7(1):44-49.
52. Boden SD, Martin GJ, Jr, Morone M, et al. The use of coralline hydroxyapatite with bone
marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral
lumbar spine fusion. Spine (Phila Pa 1976). 1999;24(4):320-327.
53. Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized
clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976).
2002;27(23):2662-2673.
54. Haid RW, Jr, Branch CL, Jr, Alexander JT, et al. Posterior lumbar interbody fusion using
recombinant human bone morphogenetic protein type 2 with cylindrical interbody
cages. Spine J. 2004;4(5):527-538; discussion 538-529.
55. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal
lumbar interbody fusion. Spine J. 2009;9(8):623-629.
56. Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for
lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age.
Spine (Phila Pa 1976). 2008;33(26):2843-2849.
57. Carreon LY, Glassman SD, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for
lumbar spine fusion in patients over 60 years of age: a cost-utility study. Spine (Phila
Pa 1976). 2009;34(3):238-243.
58. Glassman SD, Dimar JR, 3rd, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral
lumbar fusion in smokers. Spine (Phila Pa 1976). 2007;32(15):1693-1698.
59. Mummaneni PV, Pan J, Haid RW, et al. Contribution of recombinant human bone
morphogenetic protein-2 to the rapid creation of interbody fusion when used in
transforaminal lumbar interbody fusion: a preliminary report. Invited submission from
the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March
2004. J Neurosurg Spine. 2004;1(1):19-23.
60. Brown A, Stock G, Patel AA, et al. Osteogenic protein-1: a review of its utility in spinal
applications. BioDrugs. 2006;20(4):243-251.
61. Cook SD, Dalton JE, Tan EH, et al. In vivo evaluation of recombinant human osteogenic
protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine (Phila Pa
1976). 1994;19(15):1655-1663.
62. Vaccaro AR, Patel T, Fischgrund J, et al. A pilot safety and efficacy study of OP-1 putty
(rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur
Spine J. 2003;12(5):495-500.
63. Delawi D, Dhert WJ, Rillardon L, et al. A prospective, randomized, controlled, multicenter
study of osteogenic protein-1 in instrumented posterolateral fusions: report on safety
and feasibility. Spine (Phila Pa 1976). 2010;35(12):1185-1191.
64. Vaidya R. Transforaminal interbody fusion and the “off label” use of recombinant human
bone morphogenetic protein-2. Spine J. 2009;9(8):667-669.
65. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after
transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J
Spinal Disord Tech. 2006;19(7):483-486.
66. Vaidya R, Weir R, Sethi A, et al. Interbody fusion with allograft and rhBMP-2 leads to
consistent fusion but early subsidence. J Bone Joint Surg Br. 2007;89(3):342-345.
67. Vaidya R, Sethi A, Bartol S, et al. Complications in the use of rhBMP-2 in PEEK cages for
interbody spinal fusions. J Spinal Disord Tech. 2008;21(8):557-562.
68. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar
canal: a potential complication of off-label PLIFTLIF use of bone morphogenetic
protein-2 (BMP-2). Spine J. 2008;8(6):1011-1018.
69. Toth JM, Boden SD, Burkus JK, et al. Short-term osteoclastic activity induced by locally
high concentrations of recombinant human bone morphogenetic protein-2 in a
cancellous bone environment. Spine (Phila Pa 1976). 2009;34(6):539-550.
70. Vaidya R, Carp J, Sethi A, et al. Complications of anterior cervical discectomy and fusion
using recombinant human bone morphogenetic protein-2. Eur Spine J.
2007;16(8):1257-1265.
71. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with offlabel usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976).
2006;31(24):2813-2819.
72. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion
study using recombinant human bone morphogenetic protein-2 with the
CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine
(Phila Pa 1976). 2003;28(12):1219-1224; discussion 1225.
73. Carragee EJ, Mitsunaga KA, Hurwitz EL, et al. Retrograde ejaculation after anterior lumbar
interbody fusion using rhBMP-2: a cohort controlled study. Spine J. 2011;11(6):511516.
74. Lindley EM, McBeth ZL, Henry SE, et al. Retrograde ejaculation after anterior lumbar spine
surgery. Spine (Phila Pa 1976). 2012;37(20):1785-1789.
75. Burkus JK, Dryer RF, Peloza JH. Retrograde ejaculation following single-level anterior
lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5
randomized controlled trials: clinical article. J Neurosurg Spine. 2013;18(2):112-121.
76. Lubelski D, Abdullah KG, Nowacki AS, et al. Urological complications following use of
recombinant human bone morphogenetic protein-2 in anterior lumbar interbody fusion:
presented at the 2012 Joint Spine Section Meeting: clinical article. J Neurosurg Spine.
2013;18(2):126-131.
77. Tepper G, Rabbani R, Yousefzadeh M, et al. quantitative assessment of retrograde
ejaculation using semen analysis, comparison to a standardized qualitative
questionnaire, and investigating the impact of rhBMP-2. Spine (Phila Pa 1976).
2013;38(10):841-845.
78. Devine JG, Dettori JR, France JC, et al. The use of rhBMP in spine surgery: is there a cancer
risk? Evid Based Spine Care J. 2012;3(2):35-41.
79. Mines D, Gu Y, Kou TD, et al. Recombinant human bone morphogenetic protein-2 and
pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf.
2011;20(2):111-118.
80. Yang W, Dong Y, Hong Y, et al. Evaluation of anterior vertebral interbody fusion using
osteogenic mesenchymal stem cells transplanted in collagen sponge. J Spinal Disord
Tech. 2012.
81. Tohmeh AG, Watson B, Tohmeh M, et al. Allograft cellular bone matrix in extreme lateral
interbody fusion: preliminary radiographic and clinical outcomes.
ScientificWorldJournal. 2012;2012:263637.
82. Ammerman JM, Libricz J, Ammerman MD. The role of Osteocel Plus as a fusion substrate in
minimally invasive instrumented transforaminal lumbar interbody fusion. Clin Neurol
Neurosurg. 2013;115(7):991-994.
0
